SCHEMBL2136550

SCHEMBL2136550

CCOC(=O)[C@@H]1C[C@H]1c1ccc2cccnc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
P2RY14 Q15391 2/20 0.40
NOTUM Q6P988 1/20 0.39
RPS6KB1 P23443 1/20 0.39
MEN1 O00255 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 2/20 0.38
PKM P14618 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
MAPK14 Q16539 1/20 0.38
GSK3B P49841 1/20 0.37
TRPM5 Q9NZQ8 3/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2136544 1.00 ALDH1A1 (0.41) ALDH1A1P2RY14NOTUMRPS6KB1MEN1
SCHEMBL3596278 0.91 ALOX15 (0.43) ALDH1A1NOTUMMAPTRAB9A
SCHEMBL4139032 0.82 SLC6A4 (0.48)
SCHEMBL4139034 0.82 SLC6A4 (0.48)
SCHEMBL2136692 0.81 FFAR1 (0.46) ALDH1A1RPS6KB1MEN1CASP1CASP7
SCHEMBL2136695 0.81 FFAR1 (0.46) ALDH1A1RPS6KB1MEN1CASP1CASP7
SCHEMBL10086282 0.77 PDE10A (0.40) ALDH1A1MAPTCYP2C19
SCHEMBL14061648 0.77 PDE10A (0.40) ALDH1A1MAPTCYP2C19
SCHEMBL2136056 0.77 SLC6A4 (0.51) ALDH1A1NOTUMKMT2AMAPTPKM
SCHEMBL2136050 0.77 SLC6A4 (0.51) ALDH1A1NOTUMKMT2AMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522140-B2 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers RAQUALIA PHARMA INC. (JP) 2016-12-20 US disclosed
US-20150322052-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC (JP) 2015-11-12 US disclosed
US-9101616-B2 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers RAQUALIA PHARMA INC. (JP) 2015-08-11 US disclosed
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H ALDH1A1 2895/4885P2RY14 567/4885NOTUM 2983/4885
US-20150322052-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H ALDH1A1 2882/4885P2RY14 577/4885NOTUM 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.